中文摘要：

目的 探讨抗高血压药维拉帕米是否可通过下调宿主硫氧还蛋白互作蛋白（TXNIP）的表达而抑制丙型肝炎病毒（HCV）的感染。方法 用不同浓度梯度的维拉帕米处理人肝癌细胞系Huh7.5.1,用qPCR和蛋白质印迹法检测TXNIP的表达。用维拉帕米处理Huh7.5.1细胞,同时加入细胞培养产生的HCV（HCVcc）,48 h后检测HCVcc感染情况。用TXNIP siRNA转染Huh7.5.1细胞,检测下调TXNIP表达后,维拉帕米对HCVcc感染的影响;用TXNIP启动子调控的增强型绿色荧光蛋白（EGFP）报告基因表达质粒（pTXNIP-EGFP）转染Huh7.5.1细胞,分析维拉帕米对TXNIP启动子转录活性的影响。结果 与对照孔相比,维拉帕米（100、200、400μmol/L）可下调Huh7.5.1细胞中TXNIP的表达,并呈现浓度依赖性（P〈0.05）;并可抑制HCVcc对Huh7.5.1细胞的感染,且浓度越高抑制作用越明显（P〈0.05）。进一步研究结果显示,与对照组相比,维拉帕米能够抑制pTXNIP-EGFP转染细胞中EGFP的表达水平（P〈0.05）。结论 维拉帕米可下调TXNIP的表达从而抑制HCV感染,这可能是通过抑制TXNIP启动子的转录活性来实现的。

英文摘要：

Objective To investigate whether antihypertensive agent verapamil can inhibit hepatitis C virus （HCV） infection via reducing the expression of thioredoxin-interacting protein （TXNIP） in hepatocytes of the host. Methods Human hepatocellular carcinoma Huh7.5.1 cells were treated with different concentrations of verapamil, and then the mRNA and protein expressions of TXNIP were detected by qPCR and Western blotting, respectively. The HCV infection level of Huh7.5.1 cells was determined 48 h after treatment with verapamil and cell culture-derived HCV （HCVcc）. We observed the effect of verapamil on the Huh7.5.1 cells with TXNIP silenced by siRNA after infected by HCVcc. Huh7.5.1 cells were transfected with expression plasmid of enhanced green fluorescent protein （EGFP） controlled by TXNIP promoter （pTXNIP-EGFP）, and then the effect of verapamil on transcriptional activity TXNIP promoter was analyzed. Results Compared with the control group, verapamil （100, 200, 400 μmol/L） significantly inhibited TXNIP expression and HCV infection in Huh7.5.1 cells in a dose-dependent manner （P〈0.05）. Furthermore, verapamil reduced EGFP expression in Huh7.5.1 cells transfected with pTXNIP-EGFP in comparison with the control group （P〈0.05）. Conclusion Verapamil can inhibit HCV infection via reducing TXNIP expression, which may be associated with the inhibition of TXNIP promotor transcriptional activity.